Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055803 | 0.86 | ALDH1A1 (0.40) | NPC1FFAR4ALDH1A1GAATSHR | |
| SCHEMBL20406268 | 0.77 | KDM4E (0.55) | BTKALDH1A1POLB | |
| SCHEMBL12834091 | 0.77 | ALOX5AP (0.52) | BTKALOX5APFEN1FFAR4 | |
| SCHEMBL6856211 | 0.74 | ALDH1A1 (0.46) | RAB9AALDH1A1TSHRHPGD | |
| SCHEMBL12834050 | 0.74 | ERN1 (0.63) | ALOX5APFEN1FFAR4 | |
| SCHEMBL15674328 | 0.72 | FEN1 (0.62) | BTKALOX5APFEN1NPC1RAB9A | |
| SCHEMBL4529792 | 0.72 | KDM1A (0.43) | RAB9AALDH1A1NPSR1POLBL3MBTL1 | |
| SCHEMBL29501222 | 0.72 | FEN1 (0.62) | BTKALOX5APFEN1NPC1RAB9A | |
| SCHEMBL6854203 | 0.71 | ALDH1A1 (0.49) | RAB9AALDH1A1TSHR | |
| SCHEMBL4115203 | 0.71 | BTK (0.45) | BTKALOX5APFEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593433-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-26 | — | — | EP | disclosed |
| EP-2593433-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-26 | — | — | EP | disclosed |
| US-8772343-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772343-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772343-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| EP-2593433-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116285-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116285-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116285-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012007877-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116285-A1 | Chemical Compounds | SCN1A, SCN10A, SCN1B | BTK 601/4885ALOX5AP 3356/4885FEN1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.